Overview

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Status:
Completed
Trial end date:
2018-11-20
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal